Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis

被引：0
|
作者：
Onder, Halil [1 ]
机构：
[1] Yozgat City Hosp, Neurol Clin, Yozgat, Turkey
来源：
TURKISH JOURNAL OF NEUROLOGY | 2019年 / 25卷 / 02期
关键词：
Subcutaneous ofatumumab; relapsing-remitting multiple sclerosis; treatment; B-cell; SAFETY;
D O I：
10.4274/tnd.galenos.2019.05925
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [1] Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study
    Bar-Or, Amit
    Grove, Richard A.
    Austin, Daren J.
    Tolson, Jerry M.
    VanMeter, Susan A.
    Lewis, Eric W.
    Derosier, Frederick J.
    Lopez, Monica C.
    Kavanagh, Sarah T.
    Miller, Aaron E.
    Sorensen, Per S.
    [J]. NEUROLOGY, 2018, 90 (20) : E1805 - E1814
  • [2] Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Bar-Or, Amit
    Grove, Richard A.
    Tolson, Jerry M.
    Derosier, Frederick J.
    Lopez, Monica C.
    Kavanagh, Sarah T.
    Miller, Aaron E.
    [J]. NEUROLOGY, 2019, 92 (11) : 543 - 543
  • [3] Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Lewis, Ariane
    Galetta, Steven
    [J]. NEUROLOGY, 2019, 92 (11) : 542 - 542
  • [4] Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
    Kearney, Hugh
    [J]. NEUROLOGY, 2019, 92 (11) : 542 - 543
  • [5] Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis The MIRROR study (vol 90, e1805, 2018)
    [J]. NEUROLOGY, 2018, 91 (11) : 538 - 538
  • [6] Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis A phase 2 study
    Sorensen, Per S.
    Lisby, Steen
    Grove, Richard
    Derosier, Frederick
    Shackelford, Steve
    Havrdova, Eva
    Drulovic, Jelena
    Filippi, Massimo
    [J]. NEUROLOGY, 2014, 82 (07) : 573 - 581
  • [7] Relapsing-remitting multiple sclerosis
    Flores, A
    Ochoa, E
    Zamora, S
    Barrientos, UN
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2003, 214 (1-2) : 110 - 110
  • [8] Lower drug levels in proportion of patients with relapsing-remitting multiple sclerosis on subcutaneous natalizumab
    Toorop, A.
    Rispens, T.
    Nielsen, J.
    Sinnige, L.
    van Dijk, G.
    Uitdehaag, B.
    van Kempen, Z.
    Killestein, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 993 - 993
  • [9] Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada
    Bhan, Virender
    Clift, Fraser
    Baharnoori, Moogeh
    Thomas, Kimberly
    Patel, Barkha P.
    Blanchette, Francois
    Adlard, Nicholas
    Vudumula, Umakanth
    Gudala, Kapil
    Dutta, Nikkita
    Grima, Daniel
    Mouallif, Soukaina
    Farhane, Fatine
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (09)
  • [10] Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada
    Moogeh Baharnoori
    Virender Bhan
    Fraser Clift
    Kimberly Thomas
    Soukaïna Mouallif
    Nicholas Adlard
    Philip Cooney
    François Blanchette
    Barkha P. Patel
    Daniel Grima
    [J]. PharmacoEconomics - Open, 2022, 6 : 859 - 870
12345